Phase III reSURFACE 1&2 extension studies showed Ilumya offers sustained and improved results in plaque psoriasis.- Sun Pharma
Sun Pharmaceutical Industries announced further evidence of the long-term use and cost-effectiveness of Ilumya (tildrakizumab-asmn) in moderate-to-severe plaque psoriasis. Long-term analyses of the phase III reSURFACE 1 and… read more.